|
GRS
|
Dietary BCAAs in classified mode
|
Dietary BCAAs in continuous mode
|
|---|
|
T1
|
T2
|
T3
|
P for trend
|
P for interaction
|
Per 10 mg/g protein
|
P value
|
P for interaction
|
|---|
|
Total BCAAs
| | | | |
0.001
| | |
0.038
|
|
< 22 (n = 293)
|
1
|
0.56 (0.28–1.10)
|
0.46 (0.22–0.95)
|
0.040
| |
0.95 (0.88–1.03)
|
0.20
| |
|
22–24 (n = 279)
|
1
|
1.11 (0.59–2.08)
|
2.22 (1.15–4.31)
|
0.021
| |
1.05 (0.98–1.12)
|
0.17
| |
|
≥ 25 (n = 296)
|
1
|
2.19 (1.17–4.10)
|
2.90 (1.54–5.47)
|
0.001
| |
1.07 (1.00–1.15)
|
0.049
| |
|
Isoleucine
| | | | |
< 0.001
| | |
0.038
|
|
< 22 (n = 293)
|
1
|
0.60 (0.30–1.18)
|
0.50 (0.24–1.18)
|
0.07
| |
0.80 (0.57–1.13)
|
0.21
| |
|
22–24 (n = 279)
|
1
|
1.36 (0.72–2.56)
|
2.36 (1.21–4.59)
|
0.012
| |
1.23 (0.92–1.65)
|
0.16
| |
|
≥ 25 (n = 296)
|
1
|
2.53 (1.34–4.76)
|
3.29 (1.74–6.25)
|
< 0.001
| |
1.38 (1.00–1.89)
|
0.047
| |
|
Leucine
| | | | |
0.001
| | |
0.039
|
|
< 22 (n = 293)
|
1
|
0.55 (0.28–1.10)
|
0.47 (0.22–0.98)
|
0.050
| |
0.91 (0.79–1.05)
|
0.21
| |
|
22–24 (n = 279)
|
1
|
1.22 (0.65–2.28)
|
2.24 (1.15–4.35)
|
0.019
| |
1.09 (0.96–1.24)
|
0.17
| |
|
≥ 25 (n = 296)
|
1
|
2.23 (1.19–4.19)
|
3.06 (1.61–5.79)
|
0.001
| |
1.15 (1.00–1.32)
|
0.047
| |
|
Valine
| | | | |
0.003
| | |
0.037
|
|
< 22 (n = 293)
|
1
|
0.59 (0.30–1.17)
|
0.49 (0.24–1.03)
|
0.06
| |
0.81 (0.60–1.09)
|
0.17
| |
|
22–24 (n = 279)
|
1
|
1.12 (0.60–2.10)
|
2.07 (1.07–4.01)
|
0.035
| |
1.19 (0.92–1.54)
|
0.20
| |
|
≥ 25 (n = 296)
|
1
|
1.53 (0.82–2.86)
|
2.49 (1.33–4.67)
|
0.004
| |
1.31 (0.99–1.74)
|
0.06
| |
- The multivariate logistic regression was used for estimation of ORs and 95% confidence interval (CI)
- BCAAs branched-chain amino acids, GRS genetic risk score, T2D type 2 diabetes
- aResults were adjusted for age, sex, BMI, current drinkers, current smokers, exercise regularly, family history of diabetes, cardiovascular disease, red meat intake, and total energy intake
